Key result
In a real-world series of 15 patients receiving andexanet alfa for factor Xa inhibitor reversal, inpatient mortality was 40%.
Why the study?
What are the real-world outcomes and operational challenges of using andexanet alfa for factor Xa inhibitor reversal in bleeding patients?
Population
n=15 patients treated with andexanet alfa for bleeding, mean age 82 years, 73% with atrial fibrillation as…
Design
Case_series
Follow-up
Inpatient
Authors
Loading...
Urges caution with andexanet alfa in unselected bleeding; leaves open its role versus trial populations.
Observational (n=15)
No
What are the real-world outcomes and operational challenges of using andexanet alfa for factor Xa inhibitor reversal in bleeding patients?
Real-world use of andexanet alfa for factor Xa inhibitor reversal is feasible but associated with high inpatient mortality (40%) in a severely ill cohort, many of whom would not have met clinical trial inclusion criteria.
Culbreth et al. (2018) conducted an observational in Life-threatening bleeding associated with factor Xa inhibitors (n=15). Andexanet alfa was evaluated on Inpatient mortality. In a real-world series of 15 patients receiving andexanet alfa for factor Xa inhibitor reversal, inpatient mortality was 40%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: